Samsara Vision notes the CONCERTO trial will recruit 100 adults aged 65 and older living with stable (non-active neovascularization), bilateral central scotomas (blind spots) due to late-stage AMD and fovea-involving geographic atrophy or disciform scar to receive a SING IMT™ in one eye.

Recruitment begins for a new robot study jointly run by the University of Warwick, University Hospitals Coventry and Warwickshire (UHCW) NHS Trust, and the Royal Orthopaedic Hospital in Birmingham.

These results for the trial’s active treatment arm showed that chronic rhinitis symptoms continued to improve through 12 months after treatment with RhinAer.

D. Keith Grossman, Chairman, CEO and President of Nevro said, “In addition to the strong clinical efficacy for HFX Therapy that has already been shown in our landmark SENZA-PDN trial, these results demonstrate improvement in several important health-related quality of life metrics in patients with PDN.”

This trial will evaluate the safety and efficacy of the NeuroVasc ENVI™-SR, a stent-retriever intended for the treatment of acute ischemic stroke to reduce disability by removing blood clots in patients with stroke due to large vessel occlusion.